Document is current
Any future updates will be listed below
-
Authors
de Jong, Anouk C. https://orcid.org/0000-0002-7381-3171
Danyi, Alexandra https://orcid.org/0000-0002-1857-0816
van Riet, Job https://orcid.org/0000-0001-7767-7923
de Wit, Ronald
Sjöström, Martin https://orcid.org/0000-0002-2629-9966
Feng, Felix https://orcid.org/0000-0002-0963-7687
de Ridder, Jeroen https://orcid.org/0000-0002-0828-3477
Lolkema, Martijn P. https://orcid.org/0000-0003-0466-2928
-
Funding
Funding for this research was provided by:
Johnson and Johnson (212082PCR3014)
Astellas Pharma US (Lolkema/NL-72-RG-11)
- License Information
-
More Information
Article History
Received: 9 September 2022
Accepted: 22 March 2023
First Online: 8 April 2023
Competing interests
: RdW has speaker/advisory roles at Sanofi, Bayer, and Astellas, advisory roles at Orion, Hengrui, and Merck US, and received institutional research grants from Sanofi and Bayer. FF received personal fees as a consultant for Janssen, Myovant, Roivant, Novartis, Astellas, Foundation Medicine and Exact Sciences, as a member of the scientific advisory board of Bayer, SerImmune, Bristol Meyers Squibb (BMS), Bluestar Genomics, Blue Earth Diagnostics, and Tempus, as an advisor with stock options at Artera, and as former co-founder with ownership interests of PFS Genomics (relationship termed in April 2021. JdR is co-founder of Cyclomics BV. ML received advisory role/speaker fees from Incyte, Amgen, Janssen Cilag B.V., Bayer, Servier, Roche, Pfizer, Sanofi Aventis Netherlands BV, and Astellas, and has received institutional research funding from Sanofi, JnJ, Merck, and Astellas. All other authors declare no competing interests.
